Literature DB >> 33516237

Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer.

Thomas E Rohan1, Rhonda Arthur2, Yihong Wang3, Sheila Weinmann4, Mindy Ginsberg2, Sherene Loi5,6, Roberto Salgado6,7.   

Abstract

BACKGROUND: It is well established that tumors are antigenic and can induce an immune response by the host, entailing lymphocytic infiltration of the tumor and surrounding stroma. The extent and composition of the immune response to the tumor, assessed through evaluation of tumor-infiltrating lymphocyte counts, has been shown in many studies to have prognostic and predictive value for invasive breast cancer, but currently, there is little evidence regarding the association between infiltrating immune cell counts (IICCs) in women with benign breast disease (BBD) and risk of subsequent invasive breast cancer.
METHODS: Using a cohort of 15,395 women biopsied for BBD at Kaiser Permanente Northwest, we conducted a nested case-control study in which cases were women who developed a subsequent invasive breast cancer during follow-up and controls were individually matched to cases on age at BBD diagnosis. We assessed IICCs in normal tissue and in the BBD lesions, and we used unconditional logistic regression to estimate the multivariable odds ratios (OR) and 95% confidence intervals (CI) for the associations between IICCs and breast cancer risk.
RESULTS: There was no association between the IICC in normal tissue (multivariable OR per 5% increase in IICC = 1.05, 95% CI = 0.96-1.16) or in the BBD lesion (OR per 5% increase in IICC = 1.06, 95% CI = 0.96-1.18) and risk of subsequent invasive breast cancer. Also, there were no associations within subgroups defined by menopausal status, BBD histology, BMI, and history of smoking.
CONCLUSION: The results of this study suggest that IICCs in BBD tissue are not associated with altered risk of subsequent invasive breast cancer.

Entities:  

Keywords:  Benign breast disease; Breast cancer; Tumor-infiltrating lymphocytes

Mesh:

Year:  2021        PMID: 33516237      PMCID: PMC7846992          DOI: 10.1186/s13058-021-01395-x

Source DB:  PubMed          Journal:  Breast Cancer Res        ISSN: 1465-5411            Impact factor:   6.466


  14 in total

Review 1.  Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

2.  Image analysis of immune cell patterns in the human mammary gland during the menstrual cycle refines lymphocytic lobulitis.

Authors:  Nadine S Schaadt; Juan Carlos López Alfonso; Ralf Schönmeyer; Anne Grote; Germain Forestier; Cédric Wemmert; Nicole Krönke; Mechthild Stoeckelhuber; Hans H Kreipe; Haralampos Hatzikirou; Friedrich Feuerhake
Journal:  Breast Cancer Res Treat       Date:  2017-04-25       Impact factor: 4.872

3.  The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.

Authors:  G Pruneri; M Lazzeroni; V Bagnardi; G B Tiburzio; N Rotmensz; A DeCensi; A Guerrieri-Gonzaga; A Vingiani; G Curigliano; S Zurrida; F Bassi; R Salgado; G Van den Eynden; S Loi; C Denkert; B Bonanni; G Viale
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

4.  Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Authors:  Joann G Elmore; Gary M Longton; Patricia A Carney; Berta M Geller; Tracy Onega; Anna N A Tosteson; Heidi D Nelson; Margaret S Pepe; Kimberly H Allison; Stuart J Schnitt; Frances P O'Malley; Donald L Weaver
Journal:  JAMA       Date:  2015-03-17       Impact factor: 56.272

5.  Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

Authors:  Rhonda Arthur; Yihong Wang; Kenny Ye; Andrew G Glass; Mindy Ginsberg; Olivier Loudig; Thomas Rohan
Journal:  Breast Cancer Res Treat       Date:  2017-06-22       Impact factor: 4.872

6.  Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues.

Authors:  Chunyan Gu-Trantien; Soizic Garaud; Edoardo Migliori; Cinzia Solinas; Jean-Nicolas Lodewyckx; Karen Willard-Gallo
Journal:  Methods Mol Biol       Date:  2018

Review 7.  Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Authors:  Maria Vittoria Dieci; Nina Radosevic-Robin; Susan Fineberg; Gert van den Eynden; Nils Ternes; Frederique Penault-Llorca; Giancarlo Pruneri; Timothy M D'Alfonso; Sandra Demaria; Carlos Castaneda; Joselyn Sanchez; Sunil Badve; Stefan Michiels; Veerle Bossuyt; Federico Rojo; Baljit Singh; Torsten Nielsen; Giuseppe Viale; Seong-Rim Kim; Stephen Hewitt; Stephan Wienert; Sybille Loibl; David Rimm; Fraser Symmans; Carsten Denkert; Sylvia Adams; Sherene Loi; Roberto Salgado
Journal:  Semin Cancer Biol       Date:  2017-10-09       Impact factor: 15.707

Review 8.  Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.

Authors:  Lironne Wein; Peter Savas; Stephen J Luen; Balaji Virassamy; Roberto Salgado; Sherene Loi
Journal:  Front Oncol       Date:  2017-08-03       Impact factor: 6.244

9.  Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers.

Authors:  Anita Grigoriadis; Patrycja Gazinska; Trupti Pai; Sheeba Irhsad; Yin Wu; Rosemary Millis; Kalnisha Naidoo; Julie Owen; Cheryl E Gillett; Andrew Tutt; Anthonius Cc Coolen; Sarah E Pinder
Journal:  J Pathol Clin Res       Date:  2018-01-08

10.  Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Authors:  Zuzana Kos; Elvire Roblin; Rim S Kim; Stefan Michiels; Brandon D Gallas; Weijie Chen; Koen K van de Vijver; Shom Goel; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; W Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen Hewitt; Carsten Denkert; Sibylle Loibl; Stephen J Luen; John M S Bartlett; Peter Savas; Giancarlo Pruneri; Deborah A Dillon; Maggie Chon U Cheang; Andrew Tutt; Jacqueline A Hall; Marleen Kok; Hugo M Horlings; Anant Madabhushi; Jeroen van der Laak; Francesco Ciompi; Anne-Vibeke Laenkholm; Enrique Bellolio; Tina Gruosso; Stephen B Fox; Juan Carlos Araya; Giuseppe Floris; Jan Hudeček; Leonie Voorwerk; Andrew H Beck; Jen Kerner; Denis Larsimont; Sabine Declercq; Gert Van den Eynden; Lajos Pusztai; Anna Ehinger; Wentao Yang; Khalid AbdulJabbar; Yinyin Yuan; Rajendra Singh; Crispin Hiley; Maise Al Bakir; Alexander J Lazar; Stephen Naber; Stephan Wienert; Miluska Castillo; Giuseppe Curigliano; Maria-Vittoria Dieci; Fabrice André; Charles Swanton; Jorge Reis-Filho; Joseph Sparano; Eva Balslev; I-Chun Chen; Elisabeth Ida Specht Stovgaard; Katherine Pogue-Geile; Kim R M Blenman; Frédérique Penault-Llorca; Stuart Schnitt; Sunil R Lakhani; Anne Vincent-Salomon; Federico Rojo; Jeremy P Braybrooke; Matthew G Hanna; M Teresa Soler-Monsó; Daniel Bethmann; Carlos A Castaneda; Karen Willard-Gallo; Ashish Sharma; Huang-Chun Lien; Susan Fineberg; Jeppe Thagaard; Laura Comerma; Paula Gonzalez-Ericsson; Edi Brogi; Sherene Loi; Joel Saltz; Frederick Klaushen; Lee Cooper; Mohamed Amgad; David A Moore; Roberto Salgado
Journal:  NPJ Breast Cancer       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.